Brenda,

No thanks Brenda, it is normal that when I have informations I put
them on the board for the others. I post when I find some new
information or when I answer on questions made by members. How I find
such informations, only by surfing on internet. Together we make a
difference is a reality. Your PLWP site is fantastic and I have one
regret not to be with you all.
Friendly
Tina





--- In nobordersforparkinsondisease@yahoogroups.com, Brenda Tucker
<btucma2000@y...> wrote:
>
> Tina,
> Thank kyou so much for what you do. It was so good to wake this
morning and have email of three positive findings in Parkiinson's.
May I ask where you get your information. How often do you post?
This really seems like a good idea to tell the membership about. It
would almost be like getting a Wall Street Journal at your front door
every morning.
> Together we make a difference,
> Brenda Tucker, Co-Founder
> PLWP, Inc.
>
>
> To unsubscribe from this group, send an email to:
> nobordersforparkinsondisease-unsubscribe@yahoogroups.com
>
>
> --------------------------------------------------------------------
----
>
> There are 3 messages in this issue.
>
> Topics in this digest:
>
> 1. Potassium and Parkinson
> From: tina_semal
> 2. Teva sats clinical trial of PDdrug successful
> From: tina_semal
> 3. insecticide neurotoxicity yields clues to onset of PD
> From: tina_semal
>
>
>
______________________________________________________________________
__
>
______________________________________________________________________
__
>
> Message: 1
> Date: Fri, 28 Mar 2003 05:56:45 -0000
> From: tina_semal
> Subject: Potassium and Parkinson
>
> CHICAGO (Ivanhoe Newswire) -- Researchers from Northwestern
> University report symptoms of Parkinson's disease, a
> neurodegenerative disease afflicting over 1 million people in the
> United States, may be improved by blocking a specific potassium
> channel in a select group of brain cells.
>
>
> The common symptoms of Parkinson's disease, including resting
tremor,
> muscle rigidity and slowed movement, are the result of dopamine loss
> from the cell. Researchers have found a mechanism that may lessen
the
> symptoms and slow progression of the disease.
>
>
> Scientists say a potassium channel unique to the affected brain
> regions controls the cellular mechanism responsible for Parkinson's
> disease symptoms. The potassium channel, called Kv3.4, is found in a
> subset of neurons outside the basal ganglia. The basal ganglia are
> structures located deep in the brain that are responsible for normal
> movement such as walking. Neurons in another region of the brain
> contain high numbers of potassium channels that may account for the
> symptoms in Parkinson's disease patients.
>
>
> Current therapies to surgically destroy these neurons or employ
> electrode stimulation to disrupt neuronal activity provide
> symptomatic relief. They also cause unwanted side effects such as
> uncontrolled movement. "The perfect therapy for Parkinson's disease
> would be to prevent neurons from exhibiting the behavior that causes
> the symptoms … without altering their 'good' behaviors," says
> researcher James Surmeier.
>
>
> Blocking potassium channels with the Kv3.4 subunit or eliminating
the
> subunit using gene therapy techniques are two possible therapeutic
> options, the authors write. Surmeier says, "Doing so would eliminate
> the 'bad' behavior but, importantly, preserve the 'good' behavior
…
> of these neurons."
>
> Reported March 25, 2003
>
>
>
>
>
>
>
______________________________________________________________________
__
>
______________________________________________________________________
__
>
> Message: 2
> Date: Fri, 28 Mar 2003 06:11:19 -0000
> From: tina_semal
> Subject: Teva sats clinical trial of PDdrug successful
>
> Generic drug giant Teva Pharmaceuticals yesterday released two
> positive announcements: the successful completion of the Rasagiline
> phase III clinical program in Parkinson's disease; and U.S. approval
> for its versions of a drug to reduce glucose in the bloodstream.
>
>
> Teva and its drug testing partner, H. Lundbeck, yesterday said two
> phase III clinical trials of Rasagiline in patients with advanced
> Parkinson's disease had been successfully completed. Both trials
> achieved statistically significant results, Teva said.
>
>
> Each study, which compared single daily dosages of Rasagiline to a
> placebo as an added treatment to Levodopa, demonstrated significant
> reductions in the duration of the "off" time in which patients are
> unable to function normally.
>
>
> Rasagiline is now expected to be submitted for regulatory approval
in
> North America and Europe during the second half of 2003, Teva said
in
> its press release.
>
>
> Rasagiline was developed by Teva based on the original research of
> professors Moussa Youdim and John Finberg from the Haifa Technion
> School of Medicine in Israel. Youdim heads the Eve Topf
> Neurodegenerative Disease Research and Teaching Center at the
Faculty
> of Medicine at the Technion, where he develops drugs for
> neurodegenerative conditions.
>
>
> Under its agreement with Teva, Lundbeck will market Rasagiline in
> Europe and other overseas markets in a joint effort with Teva, while
> Teva retains exclusive marketing rights in the rest of the world,
> including North America.
>
>
> Meanwhile, Teva has received tentative U.S. Food and Drug
> Administration approval to market Metformin HCl extended-release
> tablets, in 50-mg dosage, the Israeli drugmaker announced yesterday.
>
>
> The brand-name product sells for about $410 million a year, Teva
> said. Metformin HCl Extended-Release Tablets are the AB-rated
generic
> equivalent of Bristol-Myers Squibb's antihyperglycemic drug,
> Glucophage XR. The tablets are prescribed together with dietary
> changes to lower blood glucose levels in patients with type two
> diabetes. Teva did not disclose whether it filed for approval under
> Paragraph four, which would grant it a six- month period of
marketing
> exclusivity.
>
>
> Analyst Ori Hershkovitz of Leader&Co says Bristol-Myers' patent on
> Glucophage expires in October 2003, after which Teva could start
> marketing its generic version. If Teva gets exclusivity, Hershkovitz
> estimates it could command revenues of $70 million in the first
year,
> with a 35-percent profit margin - meaning, it could increase Teva's
> net by $25 million.
>
>
> Without exclusivity, Hershkovitz estimates, its sales would increase
> by $20-30 million, contributing $3-5 million profits in the first
> year.
>
>
> SOURCE: Ha'aretz Daily, Israel
> http://www.haaretzdaily.com/hasen/pages/ShArt.jhtml?
itemNo=277418&cont
> rassID=2&subContrassID=2&sbSubContrassID=0&listSrc=Y
> March 27, 2003 Adar2 23, 5763
> By Ilan Mosnaim
>
>
>
>
>
______________________________________________________________________
__
>
______________________________________________________________________
__
>
> Message: 3
> Date: Fri, 28 Mar 2003 07:26:34 -0000
> From: tina_semal
> Subject: insecticide neurotoxicity yields clues to onset of PD
>
> BLACKSBURG, Va., March 24, 2003 -- A grant from the U.S. Army has
led
> Virginia Tech researchers to discover that exposure to some
> insecticides may cause a cascade of chemical events in the brain
that
> could lead to Parkinson's Disease.
>
>
> Jeffrey R. Bloomquist, a neurotoxicologist and associate professor
in
> the university's Department of Entomology, will describe his
findings
> as part of the International Award for Research in Agrochemicals, a
> symposium honoring Robert M. Hollingworth, at the annual meeting of
> the American Chemical Society in New Orleans this week.
>
>
> "We found low-level exposures set in motion a process with an early
> onset that develops slowly and is persistent," Bloomquist
said. "More
> surprising is that high-level exposures resulted in few immediate
> effects that we could observe, but in the longer term there was a
> delayed effect."
>
>
> The Virginia Tech researchers studied the levels of dopamine,
> dopamine transporter protein expression, and the levels of a
synaptic
> protein (alpha-synuclein) in mice exposed to various doses of the
> insecticide permethrin. The increase in dopamine uptake indicated
the
> mouse's system was reacting to a neurochemical insult caused by the
> presence of the insecticide. The slow response to high levels of
> exposure to pesticides is caused, Bloomquist thinks, by the system
> being overloaded and only after a period of a few weeks is it
capable
> of responding to the insult in the same way as low doses.
>
>
> In some individuals, dopamine-producing neurons may be challenged by
> genetic factors or by previous exposure to other neurotoxins. For
> individuals with a genetic predisposition, exposure to permethrin
may
> trigger chemical events in the brain that result in an increased
risk
> for damage to the area of the brain that is selectively damaged in
> Parkinson's disease.
>
>
> The loss of motor skills, resulting in symptoms such as muscle
> rigidity, shuffling gait, and a rhythmic tremor, has been linked to
> the loss of dopamine production in the brain. That loss of dopamine
> is the major neurochemical expression of Parkinson's Disease.
>
>
> "Our studies have documented low-dose effects of permethrin, doses
> below one-one thousandth of a lethal dose for a mouse, with effects
> on those brain pathways involved in Parkinson's Disease," he said.
> "We have found effects consistent with a pre-parkinsonsian
condition,
> but not yet full-blown parkinsonism."
>
>
> Bloomquist also found permethrin exposure resulted in an
> overproduction of the protein alpha-synuclein at low doses. The
> accumulation of the protein is a major component of the formation of
> the Lewy bodies, fibrous tangles observed in the brains of patients
> with Parkinson's Disease.
>
>
> The studies so far have concentrated on two-week exposures in mice.
> Bloomquist hopes to continue the work, looking at longer-term
> exposure. He is also studying the effects of another widely used
> pesticide, chlorpyrifos.
>
>
> Bloomquist and his co-investigator, Dr. Bradley Klein, are supported
> by a five year, $584,558 grant from the United States Army Medical
> Research and Materiel Command. One purpose of the Neurotoxin
Exposure
> Treatment Research Program, under which the project was funded, is
to
> determine if military operational and deployment exposures increase
> risks for neurodegenerative disease and, if so, determine means of
> protecting troops.
>
>
> "Permethrin is used worldwide in agriculture and urban settings,"
> Bloomquist said. "Widespread human exposure to this compound occurs,
> so its effects are not limited to soldiers."
>
>
> The talk, "Low-dose effects of insecticides to dopaminergic pathways
> involved in parkinsonism" (AGRO 31) will be presented at 2 p.m.
> Monday, March 24, in the Hampton Inn Convention Center Fulton room.
>
>
>
>
>
>
>
______________________________________________________________________
__
>
______________________________________________________________________
__
>
>
>
> Your use of Yahoo! Groups is subject to
http://docs.yahoo.com/info/terms/
>
>
>
>
> ---------------------------------
> Do you Yahoo!?
> Yahoo! Platinum - Watch CBS' NCAA March Madness, live on your
desktop!
>
> [Non-text portions of this message have been removed]